MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mata, J. F.
Right arrow Articles by Pastor-Anglada, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mata, J. F.
Right arrow Articles by Pastor-Anglada, M.

Vol. 59, Issue 6, 1542-1548, June 2001

Role of the Human Concentrative Nucleoside Transporter (hCNT1) In the Cytotoxic Action of 5[Prime]-Deoxy-5-fluorouridine, an Active Intermediate Metabolite of Capecitabine, a Novel Oral Anticancer Drug

João F. Mata, José M. García-Manteiga, M. Pilar Lostao, Sonia Fernández-Veledo, Elena Guillén-Gómez, Ignacio M. Larrayoz, Jorge Lloberas, F. Javier Casado, and Marçal Pastor-Anglada

Departament de Bioquímica i Biologia Molecular (J.F.M., J.M.G.-M., S.F.V., E.G.-G., F.J.C., M.P.-A.) and Departament de Fisiologia (Immunologia) (J.L.), Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain and Departamento de Fisiología y Nutrición, Universidad de Navarra, Pamplona, Spain (M.P.L., I.M.L.)

We attempt to identify the plasma membrane transporter involved in the uptake of 5'-deoxy-5-fluorouridine (5'-DFUR), an intermediate metabolite of capecitabine. This novel oral fluoropyrimidine is used in cancer treatments and is a direct precursor of the cytostatic agent 5'-fluorouracil. We also examine the role of the transporter in 5'-DFUR cytotoxicity. The human concentrative nucleoside transporter (hCNT1) was cloned from human fetal liver and expressed in Xenopus laevis oocytes. The two-electrode voltage-clamp technique was used to demonstrate that 5'-DFUR, but not capecitabine or 5'-FU, is an hCNT1 substrate. Then, hCNT1 was heterologously expressed in the mammalian cell line Chinese hamster ovary-K1. Functional expression was demonstrated by monitoring transport of radiolabeled substrates and by using a monospecific polyclonal antibody generated against the transporter. hCNT1-expressing cells were more sensitive to 5'-DFUR than vector-transfected or wild-type cells. The sensitivity of the three cell types to other agents such as cisplatin or 5'-FU was identical. In conclusion, this study shows that 1) the pharmacological profile of a nucleoside transporter can be determined by an electrophysiological approach; 2) the hCNT1 transporter is involved in 5'-DFUR uptake; and 3) hCNT1 expression may increase cell sensitivity to 5'-DFUR treatment. This study also reports for the first time the generation of an antibody against hCNT1, which may be useful in the elucidation of the relationship between hCNT1 expression and tumor response to capecitabine treatment.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
G. Minuesa, S. Purcet, I. Erkizia, M. Molina-Arcas, M. Bofill, N. Izquierdo-Useros, F. J. Casado, B. Clotet, M. Pastor-Anglada, and J. Martinez-Picado
Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 558 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. Errasti-Murugarren, P. Cano-Soldado, M. Pastor-Anglada, and F. J. Casado
Functional Characterization of a Nucleoside-Derived Drug Transporter Variant (hCNT3C602R) Showing Altered Sodium-Binding Capacity
Mol. Pharmacol., February 1, 2008; 73(2): 379 - 386.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. Govindarajan, A. H. Bakken, K. L. Hudkins, Y. Lai, F. J. Casado, M. Pastor-Anglada, C.-M. Tse, J. Hayashi, and J. D. Unadkat
In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1809 - R1822.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
E. Errasti-Murugarren, M. Pastor-Anglada, and F. J. Casado
Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs
J. Physiol., August 1, 2007; 582(3): 1249 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
I. M. Larrayoz, A. Fernandez-Nistal, A. Garces, E. Gorraitz, and M. P. Lostao
Characterization of the rat Na+/nucleoside cotransporter 2 and transport of nucleoside-derived drugs using electrophysiological methods
Am J Physiol Cell Physiol, December 1, 2006; 291(6): C1395 - C1404.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H. Hu, C. J. Endres, C. Chang, N. S. Umapathy, E.-W. Lee, Y.-J. Fei, S. Itagaki, P. W. Swaan, V. Ganapathy, and J. D. Unadkat
Electrophysiological Characterization and Modeling of the Structure Activity Relationship of the Human Concentrative Nucleoside Transporter 3 (hCNT3)
Mol. Pharmacol., May 1, 2006; 69(5): 1542 - 1553.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. T. Lang, J. D. Young, and C. E. Cass
Interactions of Nucleoside Analogs, Caffeine, and Nicotine with Human Concentrative Nucleoside Transporters 1 and 2 Stably Produced in a Transport-Defective Human Cell Line
Mol. Pharmacol., April 1, 2004; 65(4): 925 - 933.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
I. M. Larrayoz, F. J. Casado, M. Pastor-Anglada, and M. P. Lostao
Electrophysiological Characterization of the Human Na+/Nucleoside Cotransporter 1 (hCNT1) and Role of Adenosine on hCNT1 Function
J. Biol. Chem., March 5, 2004; 279(10): 8999 - 9007.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Garcia-Manteiga, M. Molina-Arcas, F. J. Casado, A. Mazo, and M. Pastor-Anglada
Nucleoside Transporter Profiles in Human Pancreatic Cancer Cells: Role of hCNT1 in 2',2'-Difluorodeoxycytidine- Induced Cytotoxicity
Clin. Cancer Res., October 15, 2003; 9(13): 5000 - 5008.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Molina-Arcas, B. Bellosillo, F. J. Casado, E. Montserrat, J. Gil, D. Colomer, and M. Pastor-Anglada
Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia
Blood, March 15, 2003; 101(6): 2328 - 2334.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Soler, R. Valdes, J. Garcia-Manteiga, J. Xaus, M. Comalada, F. J. Casado, M. Modolell, B. Nicholson, C. MacLeod, A. Felipe, et al.
Lipopolysaccharide-induced Apoptosis of Macrophages Determines the Up-regulation of Concentrative Nucleoside Transporters Cnt1 and Cnt2 through Tumor Necrosis Factor-alpha -dependent and -independent Mechanisms
J. Biol. Chem., August 3, 2001; 276(32): 30043 - 30049.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics